# GIGAMUNE, INC.: A Novel Lentivector for Enhanced In Vivo Delivery of T Cell Receptors for Cell Therapy for Stage IV Melanoma

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | GIGAMUNE, INC. |
| Location | SAN FRANCISCO, CA |
| Project | A Novel Lentivector for Enhanced In Vivo Delivery of T Cell Receptors for Cell Therapy for Stage IV Melanoma |
| Project number | 4R44CA310160-02 |
| Mechanism | R44 |
| Institute | National Cancer Institute |
| Award | $1,000,000 |
| Awarded | 2026-09-09 |
| Project period | 2025-09-15 to 2028-08-31 |
| UEI | KD8GTLK3VV93 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11457449). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.